Solabegron | Wikipedia audio article
Channel: wikipedia tts
Date: 28/10/2018

This is an audio version of the Wikipedia Article:
Solabegron

Listening is a more natural way of learning, when compared to reading. Written
language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through
audio (audio article). You could even learn subconsciously by playing the audio
while you are sleeping! If you are planning to listen a lot, you could try using
a bone conduction headphone, or a standard speaker instead of an earphone.


You can find other Wikipedia audio articles too at:
https://www.youtube.com/channel/UCuKfABj2eGyjH3ntPxp4YeQ

In case you don't find one that you were looking for, put a comment.
This video uses Google TTS en-US-Standard-D voice.



SUMMARY
=======
Solabegron (code name GW-427,353) is a drug which acts as a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome. It has been shown to produce visceral analgesia by releasing somatostatin from adipocytes.Solabegron was discovered by GlaxoSmithKline and acquired by AltheRx in March 2011. Solabegron relaxes the bladder smooth muscle by stimulating β3 adrenoceptors, a novel mechanism compared with older established drug treatments for overactive bladder syndrome such as the anticholinergic agents. Astellas Pharma has developed the first commercially available β3 adrenergic receptor, mirabegron, which is now licensed in Japan and the U.S. for overactive bladder. Mirabegron is not licensed for irritable bowel syndrome.
A Phase II study of solabegron for overactive bladder (OAB) looked at 258 patients with moderate-to-severe incontinence experiencing an average of 4.5 wet episodes per day. Results demonstrated a statistically significant improvement with solabegron as compared with placebo, as measured by the percentage reduction of the number of wet episodes and the absolute number of daily voids.
A Phase II study for irritable bowel syndrome (IBS) evaluated 102 patients with IBS. Solabegron demonstrated significant reduction in pain associated with the disorder and a trend for greater improvement in the quality of life, when compared with a placebo.
Both Phase II studies indicated a tolerability profile for solabegron that was similar to placebo. The OAB patients did not suffer from dry mouth, constipation, increase in heart rate or cognitive issues (i.e. anticholinergic effects).
AltheRx is currently preparing to advance solabegron into a large clinical study in OAB.